|
Hematologic Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
IDH1 mutations have been described in an array of hematologic malignancies and solid tumors.
|
29670690 |
2018 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
From a phase 1 study of 258 patients with IDH1-mutant advanced hematologic malignancies, we report results for 34 patients with newly diagnosed acute myeloid leukemia (AML) ineligible for standard therapy who received ivosidenib 500 mg once daily.
|
31841594 |
2020 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Inhibition of mutant IDH shows promise as a treatment approach in hematologic malignancies, with further development ongoing in solid tumors and glioma.
|
27005468 |
2016 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in the IDH1 and IDH2 (isocitrate dehydrogenase) genes have been discovered across a range of solid-organ and hematologic malignancies, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma.
|
24760710 |
2014 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Other than brain tumor or hematologic malignancies, intrahepatic cholangiocarcinoma (iCC) is a well-known solid tumor with IDH1 mutation (6.8-20%).
|
28403884 |
2017 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Since 2013, several mutant IDH-targeted inhibitors have been developed, and nearly a dozen clinical trials have opened specifically for IDH-mutant hematologic malignancies.
|
29064021 |
2017 |
|
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and prognostic impact remain to be explored in large extensively characterized AML series, and also in various other hematologic malignancies.
|
20538800 |
2010 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of this study is to determine whether germline isocitrate dehydrogenase genes mutations are involved.We targeted IDH1 and IDH2 genes in 104 familial cases belonging to Tunisian and French populations, including several forms of hematological malignancies and cosegregated solid tumors.We report one IDH1 variant: c.315 G>T, p.Gly105Gly in 15 % of cases, which was assigned to the worst outcome in several studies.
|
27591990 |
2016 |
|
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The importance of the TET-mediated cytosine demethylation pathway is also underscored by a recurrent mutation of isocitrate dehydrogenase 1 (IDH1) and IDH2 in hematological malignancies, whose mutation inhibits TET function through a novel oncometabolite, 2-hydroxyglutarate.
|
25040794 |
2014 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The mutations of isocitrate dehydrogenase 1 (IDH1) gene have been identified in a proportion of hematologic malignancies including acute myeloid leukemia (AML).
|
21539821 |
2011 |
|
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The somatic mutations of isocitrate dehydrogenase genes (IDH1 and IDH2) have been identified in a proportion of hematologic malignancies.
|
21997850 |
2012 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These findings supported initiation of the ongoing clinical trials of AG-221 in patients with <i>IDH2</i> mutation-positive advanced hematologic malignancies.<b>Significance:</b> Mutations in <i>IDH1/2</i> are identified in approximately 20% of patients with AML and contribute to leukemia via a block in hematopoietic cell differentiation.
|
28193778 |
2017 |
|
Hematologic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
URGENTseq enables the reporting of selected genes useful for immediate diagnosis (CALR, CSF3R, JAK2, KRAS, MPL, NPM1, NRAS, SF3B1) and treatment decisions (IDH1, IDH2) in hematologic malignancies within 48 hours of specimen collection.
|
30577887 |
2019 |
|
Hematologic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We here summarize the basic physiology of IDH, the metabolic and oncogenic consequences of mutant IDH1/2, and the clinical significance of IDH inhibition in hematologic malignancies.
|
28315358 |
2017 |